

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Epiworld International Co., Ltd.
瀚天天成电子科技(厦门)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2726)

INSIDE INFORMATION
APPLICATION FOR THE FULL CIRCULATION OF
H SHARES BY THE COMPANY

This announcement is made by Epiworld International Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules, namely under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

References are made to the China Securities Regulatory Commission (the “**CSRC**”) Announcement [2019] No. 22 “Guidelines on Application for ‘Full Circulation’ of Domestic Unlisted Shares of H-share Companies” (《H 股公司境内未上市股份申请“全流通”业务指引》) issued by the CSRC on November 14, 2019 and amended on August 10, 2023, and the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (《境内企业境外发行证券和上市管理试行办法》) issued by the CSRC on February 17, 2023 regarding the procedures to apply for full circulation of shares by companies whose H shares are listed on the Stock Exchange.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company has submitted an application (the “**Application**”) to the CSRC on July 10, 2026 to implement the H share full circulation (the “**H Share Full Circulation**”) in respect of the conversion of 298,038,648 unlisted shares of the Company (the “**Unlisted Shares**”), representing approximately 70.03% of the total issued share capital of the Company as at the date of this announcement, into overseas listed shares that are listed on the Stock Exchange (the “**H Shares**”) of the Company. The Company will also apply to the Stock Exchange for the listing of and permission to deal in such H Shares on the Main Board of the Stock Exchange (the “**Conversion and Listing**”).

Subject to obtaining all the relevant registration with and/or approvals from the relevant regulatory authorities (including but not limited to the CSRC and the Stock Exchange) and the compliance with all the applicable laws and regulations, such Unlisted Shares shall be converted into H Shares and be eligible to be listed and traded on the Main Board of the Stock Exchange.

Pursuant to the articles of association of the Company, no further approval from the Company's shareholder meeting will be required for the H Share Full Circulation. As at the date of this announcement, the Company (i) has not completed the registration and filings with the CSRC in respect of the Application; (ii) has not yet applied to the Stock Exchange for the Conversion and Listing; and (iii) the details of the implementation plan in relation to the H Share Full Circulation have not been finalized. The Company will make further announcements on the progress and details of the Application and the H Share Full Circulation as and when appropriate.

The H Share Full Circulation and the Conversion and Listing are subject to the relevant procedures under the requirements of the CSRC, the Stock Exchange and other relevant domestic and overseas regulatory authorities. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Epiworld International Co., Ltd.
Dr. Zhao Jianhui
Chairman and Executive Director

Hong Kong, July 10, 2026

As at the date of this announcement, the Board comprises (i) Dr. Zhao Jianhui and Ms. Pan Menghan as executive Directors; (ii) Ms. Xie Jieping and Ms. Guo Danxia as non-executive Directors; and (iii) Dr. Kang Junyong, Dr. Liao Yi and Dr. Su Xinlong as independent non-executive Directors.